Skip to main content
Journal cover image

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Publication ,  Journal Article
Cohen, JA; Baldassari, LE; Atkins, HL; Bowen, JD; Bredeson, C; Carpenter, PA; Corboy, JR; Freedman, MS; Griffith, LM; Lowsky, R; Majhail, NS ...
Published in: Biol Blood Marrow Transplant
May 2019

Multiple sclerosis (MS) is a chronic, disabling, immune-mediated, demyelinating and degenerative disease of the central nervous system. Approved disease-modifying therapies may be incompletely effective in some patients with highly active relapsing disease and high risk of disability. The use of immunoablative or myeloablative therapy followed by autologous hematopoietic cell transplantation (AHCT) has been investigated in retrospective studies, clinical trials, and meta-analyses/systematic reviews as an approach to address this unmet clinical need. On behalf of the American Society for Blood and Bone Marrow Transplantation (ASBMT), a panel of experts in AHCT and MS convened to review available evidence and make recommendations on MS as an indication for AHCT. A review of recent literature identified 8 retrospective studies, 8 clinical trials, and 3 meta-analyses/systematic reviews. In aggregate, these studies indicate that AHCT is an efficacious and safe treatment for active relapsing forms of MS to prevent clinical relapse, magnetic resonance imaging-detectable lesion activity, and worsening disability and to reverse disability without unexpected adverse events. Based on the available evidence, the ASBMT recommends that treatment-refractory relapsing MS with high risk of future disability be considered a "standard of care, clinical evidence available" indication for AHCT. Collaboration of neurologists with expertise in treating MS and transplantation physicians with experience performing AHCT for autoimmune disease is crucial for ensuring appropriate patient selection and optimizing transplantation procedures to improve patient outcomes. Transplantation centers in the United States and Canada are strongly encouraged to report baseline and outcomes data on patients receiving AHCT for multiple sclerosis to the Center for International Blood and Marrow Transplant Research.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Biol Blood Marrow Transplant

DOI

EISSN

1523-6536

Publication Date

May 2019

Volume

25

Issue

5

Start / End Page

845 / 854

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Transplantation, Autologous
  • Societies, Medical
  • Salvage Therapy
  • Patient Care Team
  • Multiple Sclerosis
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cohen, J. A., Baldassari, L. E., Atkins, H. L., Bowen, J. D., Bredeson, C., Carpenter, P. A., … Georges, G. E. (2019). Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 25(5), 845–854. https://doi.org/10.1016/j.bbmt.2019.02.014
Cohen, Jeffrey A., Laura E. Baldassari, Harold L. Atkins, James D. Bowen, Christopher Bredeson, Paul A. Carpenter, John R. Corboy, et al. “Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant 25, no. 5 (May 2019): 845–54. https://doi.org/10.1016/j.bbmt.2019.02.014.
Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, et al. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 May;25(5):845–54.
Cohen, Jeffrey A., et al. “Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant, vol. 25, no. 5, May 2019, pp. 845–54. Pubmed, doi:10.1016/j.bbmt.2019.02.014.
Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 May;25(5):845–854.
Journal cover image

Published In

Biol Blood Marrow Transplant

DOI

EISSN

1523-6536

Publication Date

May 2019

Volume

25

Issue

5

Start / End Page

845 / 854

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Transplantation, Autologous
  • Societies, Medical
  • Salvage Therapy
  • Patient Care Team
  • Multiple Sclerosis
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation